

Peter J Bailey

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2805274/peter-j-bailey-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

6,305
citations

14
h-index

19
g-index

19
ext. papers

8,077
ext. citations

16
avg, IF

3.75
L-index

#	Paper	IF	Citations
17	Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016 , 531, 47-52	50.4	1785
16	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015 , 518, 495-501	50.4	1579
15	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2017 , 32, 185-203. DOI: 10.1016/j.ccr.2017.05.013	24.3	13896
14	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015 , 521, 489-94	50.4	890
13	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2016 , 29, 832-845	24.3	442
12	Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. <i>Nature Communications</i> , 2014 , 5, 5224	17.4	176
11	Hypermethylation In Pancreatic Cancer. <i>Gastroenterology</i> , 2017 , 152, 68-74.e2	13.3	130
10	CSF1R Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. <i>Cell Reports</i> , 2018 , 23, 1448-1460	10.6	105
9	Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2016 , 6, 35848	4.9	87
8	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. <i>Journal of Pathology</i> , 2015 , 237, 363-78	9.4	72
7	BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. <i>British Journal of Cancer</i> , 2017 , 116, 1021-1026	8.7	48
6	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. <i>Cancer Cell</i> , 2020 , 38, 198-211.e8	24.3	38
5	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. <i>Cell Reports</i> , 2020 , 31, 107625	10.6	34
4	Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. <i>Cancer Research</i> , 2019 , 79, 5316-5327	10.1	19
3	Clinical Impact of Molecular Subtyping of Pancreatic Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 743908	5.7	4
2	PDAC Subtypes/Stratification. <i>Molecular and Translational Medicine</i> , 2020 , 117-128	0.4	0
1	Using Chromatin Accessibility to Delineate Therapeutic Subtypes in Pancreatic Cancer Patient-Derived Cell Lines. <i>STAR Protocols</i> , 2020 , 1, 100079	1.4	0

